Litigation Details for Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Docket		Date Filed	2013-06-24
Court	District Court, N.D. California	Date Terminated	2013-11-12
Cause	35:145 Patent Infringement	Assigned To	Maxine M. Chesney
Jury Demand	None	Referred To
Parties	AMGEN INC.
Patents	12,128,137
Attorneys	Kelly A. Krellner
Firms	Kelly A. Krellner
Link to Docket	External link to docket

Details for Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-24				External link to document

Sandoz Inc. v. Amgen Inc. Litigation Summary and Patent Analysis, 3:13-cv-02904

Last updated: September 3, 2026

Sandoz Inc. v. Amgen Inc., No. 3:13-cv-02904, was the central U.S. dispute over the Biologics Price Competition and Innovation Act's patent-disclosure and notice procedures. The case involved Sandoz's biosimilar version of Amgen's filgrastim product Neupogen. It produced the U.S. Supreme Court's leading decision on whether a biosimilar applicant must participate in the statutory "patent dance" and when it may provide commercial-marketing notice.

Sandoz ultimately obtained FDA approval for Zarxio, the first biosimilar approved in the United States. Amgen did not obtain an injunction blocking launch based on the BPCIA procedures. The Supreme Court held that the patent-dance disclosure requirement could not be enforced through a federal injunction, while commercial-marketing notice could be given before FDA approval. The decision reduced procedural leverage for reference-product sponsors and accelerated the path for biosimilar launches.

What was Sandoz Inc. v. Amgen Inc. about?

The dispute concerned Sandoz's proposed biosimilar filgrastim product and Amgen's Neupogen biologic.

Sandoz filed suit seeking declaratory relief concerning Amgen's patent rights and the operation of the BPCIA. After Sandoz submitted its biosimilar application to the FDA, it did not provide Amgen with the application and manufacturing information described in Section 351(l)(2)(A) of the Public Health Service Act. Sandoz also gave Amgen notice of commercial marketing before the FDA approved the product.

Amgen argued that:

• Sandoz was required to disclose its biosimilar application and manufacturing information.
• Sandoz's commercial-marketing notice was ineffective because it preceded FDA approval.
• The statutory patent process entitled Amgen to additional time before commercial launch.

Sandoz argued that the disclosure process was optional and that its preapproval notice was valid.

The legal dispute therefore focused less on the scientific comparability of filgrastim and more on the statutory mechanics governing biosimilar patent litigation.

What were the key procedural dates in the case?

Date	Event
May 2013	Sandoz filed the declaratory-judgment action in the U.S. District Court for the District of New Jersey.
2013-2014	Sandoz submitted its biosimilar application and provided Amgen with commercial-marketing notice before FDA approval.
2014	The district court addressed Amgen's claims concerning the BPCIA patent-disclosure and notice provisions.
March 6, 2015	FDA approved Sandoz's filgrastim product, Zarxio.
July 21, 2015	The Federal Circuit issued its decision in Amgen Inc. v. Sandoz Inc., 794 F.3d 1347.
September 2015	Sandoz launched Zarxio in the United States.
June 12, 2017	The Supreme Court issued its decision in Sandoz Inc. v. Amgen Inc., 582 U.S. 1.
2017	The Federal Circuit addressed the consequences of the Supreme Court's ruling and confirmed that preapproval notice could be effective.

The Supreme Court case was captioned Sandoz Inc. v. Amgen Inc., 582 U.S. 1, 137 S. Ct. 1664 (2017). The Federal Circuit appeal was captioned Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).

What did the district court decide?

The district court rejected Amgen's effort to prevent Zarxio's launch based on Sandoz's handling of the BPCIA process.

The district court treated the statutory disclosure process as unavailable for a federal injunction in the circumstances presented. It also concluded that Sandoz's preapproval commercial-marketing notice was not effective under the statute as then interpreted. The Federal Circuit later modified both aspects of that analysis.

The district court proceedings established the factual setting for the Supreme Court's review:

1. Sandoz had not provided Amgen with the application and manufacturing information contemplated by Section 351(l)(2)(A).
2. Sandoz had provided notice of commercial marketing before FDA approval.
3. Amgen sought an injunction and additional time before launch.
4. Zarxio received FDA approval while the dispute was pending.

The case moved to the Federal Circuit because the parties disagreed over whether the BPCIA supplied a federal remedy for noncompliance and whether preapproval notice triggered the statutory 180-day period.

What did the Federal Circuit initially hold?

The Federal Circuit's 2015 decision gave Amgen a stronger procedural position than the district court had recognized.

The court held that:

• A biosimilar applicant's disclosure of its application and manufacturing information under Section 351(l)(2)(A) was mandatory.
• A biosimilar applicant could not provide effective commercial-marketing notice until after FDA approval.
• The statutory notice period therefore could delay commercial marketing after approval.

The Federal Circuit treated the 180-day notice period as a second-stage protection for the reference-product sponsor. Under that interpretation, a sponsor could receive six additional months after approval before the biosimilar entered the market.

The decision created significant launch uncertainty for biosimilar applicants. An applicant that disclosed its application but provided notice before approval could face a potential postapproval waiting period. An applicant that withheld the application faced possible federal injunctive relief.

What did the U.S. Supreme Court decide?

The Supreme Court reversed the Federal Circuit's interpretation of the BPCIA's enforcement structure.

The Court held two principal points:

1. The BPCIA does not provide a federal injunction to enforce the applicant's duty to disclose its application and manufacturing information under Section 351(l)(2)(A).
2. A biosimilar applicant may provide commercial-marketing notice before FDA approval.

The Court reasoned that Congress established a detailed patent-litigation process but did not create a federal cause of action or federal injunction for failure to provide the application information. Instead, the statute gives the reference-product sponsor other remedies, including the ability to commence patent litigation under Section 351(l)(9)(C).

The Court also rejected the Federal Circuit's requirement that commercial-marketing notice follow FDA approval. The statutory text permits notice before approval, so the 180-day period is not automatically added after every biosimilar approval.

The decision did not eliminate the BPCIA's patent procedures. It changed the consequences of noncompliance and removed a significant delay mechanism for biosimilar launches (Sandoz Inc. v. Amgen Inc., 2017).

What was the effect on Zarxio's FDA approval and launch?

FDA approved Zarxio on March 6, 2015, under the abbreviated approval pathway for biosimilars. The product is a biosimilar to Neupogen, whose active ingredient is filgrastim.

FDA approval covered the indications and conditions of use for which Sandoz demonstrated biosimilarity to Neupogen. Zarxio launched in the United States in September 2015 after the dispute over launch timing reached the appellate courts.

The product became the first FDA-approved biosimilar in the United States. Its approval established the commercial and regulatory framework later used by other biosimilar products.

The case did not result in a court order preventing Zarxio from entering the market based on Amgen's BPCIA claims.

What patents protected Neupogen and filgrastim?

The litigation involved Amgen's patent rights relating to recombinant human granulocyte colony-stimulating factor, or G-CSF, the active biological substance in filgrastim products.

Key patents associated with the Neupogen patent estate included:

Patent	General subject matter	Relevance
U.S. Patent No. 5,580,755	DNA and recombinant production technology for human G-CSF	Core technology associated with recombinant filgrastim
U.S. Patent No. 5,849,883	G-CSF-related pharmaceutical compositions and uses	Potential composition and therapeutic coverage
Other Amgen patents	Manufacturing, formulations, and related biologic production technologies	Potential secondary barriers depending on product and process

The '755 patent expired in December 2013. That expiration removed the principal foundational patent barrier for filgrastim products. The remaining litigation risk depended on the scope, validity, enforceability, and expiration of later-filed patents.

The case therefore illustrates a common biosimilar pattern: expiration of a foundational biologic patent does not necessarily eliminate all patent risk, but it can materially reduce the reference sponsor's ability to block entry.

Does the Orange Book list Zarxio or Neupogen patents?

No. The Orange Book principally lists patents and exclusivity for FDA-approved small-molecule drugs. Neupogen and Zarxio are biologics, so their relevant regulatory exclusivity information is not presented through the Orange Book in the same manner.

Biologic patent and exclusivity analysis requires separate review of:

• The FDA Purple Book.
• The Public Health Service Act.
• The BPCIA's 12-year reference-product exclusivity period.
• Patent assignments and continuation applications.
• District court and Federal Circuit litigation.
• FDA approval records and product labeling.

The Orange Book is therefore not the correct primary source for the Neupogen-Zarxio patent estate.

Was this a Paragraph IV challenge?

The dispute was not a conventional Hatch-Waxman Paragraph IV case.

Paragraph IV certifications apply to abbreviated new drug applications for small-molecule drugs under the Federal Food, Drug, and Cosmetic Act. Zarxio was approved under the BPCIA's abbreviated biologics pathway, not through an ANDA.

The functional equivalent was Sandoz's declaratory and patent-litigation position that its biosimilar product could be marketed without infringement liability under the patents asserted or identified by Amgen. The applicable mechanism was the BPCIA patent-dance process, not a Paragraph IV certification.

The distinction matters because:

• BPCIA litigation has different disclosure and notice rules.
• Biologic reference-product exclusivity operates differently from small-molecule exclusivity.
• The BPCIA does not use the Orange Book's automatic 30-month stay structure.
• Biosimilar applicants can face patent claims involving manufacturing processes, formulations, and methods of treatment.

How strong was Amgen's patent estate after the litigation?

Amgen's patent position was materially weaker after expiration of the core filgrastim patent and the Supreme Court's limitation of procedural remedies.

Legal strengths

Amgen retained potential protection through:

• Later-expiring patents.
• Manufacturing-process claims.
• Formulation claims.
• Method-of-use claims.
• Patents covering delivery devices or presentation-specific features.
• Patents not fully resolved in the initial BPCIA dispute.

These patents could support damages claims or targeted injunction requests if a biosimilar product practiced the claimed technology.

Legal weaknesses

The estate had several limitations:

• The foundational '755 patent had expired before Zarxio's launch.
• The Supreme Court removed a federal injunction remedy for failure to disclose the biosimilar application.
• Preapproval commercial-marketing notice was valid.
• A sponsor could not automatically obtain a six-month postapproval delay through the notice provision.
• Biosimilar applicants could avoid the formal patent dance while accepting other litigation consequences.

The resulting estate was better characterized as a selective enforcement portfolio than as a complete market-blocking barrier.

What manufacturing and formulation barriers remained?

Manufacturing patents can be more important than composition patents after a biologic's core patent expires. Filgrastim products require cell-line development, recombinant expression, purification, folding, formulation, analytical characterization, and sterile manufacture.

Potential risk areas included:

• Host-cell and expression-system claims.
• Fermentation and purification steps.
• Refolding and aggregate-control processes.
• Stabilizers and excipients.
• Concentration and container-closure systems.
• Prefilled syringes and delivery devices.
• Manufacturing specifications that affect comparability.

A biosimilar applicant does not need to use the reference sponsor's manufacturing process. That limits the practical value of process patents unless the claims are broad enough to cover commercially reasonable alternatives or the applicant's selected process.

Formulation patents can create more targeted exposure because a commercial product may use specific excipients, concentrations, or presentations. Their value depends on whether the biosimilar can launch with a noninfringing formulation or dosage form.

What was the commercial impact of Zarxio?

Zarxio introduced direct U.S. competition to Neupogen. The commercial effect was greater in settings where filgrastim is reimbursed through hospital, clinic, or specialty-pharmacy purchasing channels.

The principal competitive effects included:

• Price pressure on reference filgrastim.
• Greater negotiating leverage for health systems and payers.
• Increased use of biosimilar contracting strategies.
• A regulatory precedent for later biosimilar products.
• Reduced reliance on patent-based launch delays.

Zarxio did not compete directly with pegfilgrastim products in every clinical and commercial use. Filgrastim and pegfilgrastim differ in dosing schedules, product characteristics, and market positioning. Amgen's Neulasta estate therefore required separate analysis from the Neupogen-Zarxio dispute.

How does the case compare with small-molecule generic litigation?

Issue	Zarxio biosimilar litigation	Hatch-Waxman generic litigation
Regulatory pathway	BPCIA abbreviated biologics application	ANDA
Core certification	BPCIA patent disclosure and notice	Paragraph IV certification
Orange Book	Generally not applicable	Central patent-listing source
Automatic stay	No standard 30-month Orange Book stay	Available under Hatch-Waxman
Reference exclusivity	Biologic reference-product exclusivity	New chemical entity and other FDA exclusivities
Product substitution	Depends on interchangeability and state law	Generally governed by generic substitution rules
Litigation trigger	BPCIA procedures or patent infringement action	Paragraph IV notice and infringement suit

Sandoz v. Amgen is therefore a foundational biosimilar case, not a generic-drug Paragraph IV precedent.

What was the final litigation status?

The Supreme Court's 2017 decision resolved the principal statutory issues:

• Amgen could not obtain a federal injunction solely to force Sandoz to disclose its application under Section 351(l)(2)(A).
• Sandoz's preapproval commercial-marketing notice was valid.
• The BPCIA did not automatically provide Amgen with an additional six-month postapproval delay.

The case did not establish that all Amgen patents were invalid or unenforceable. It resolved the BPCIA procedural questions and allowed the Zarxio launch path to proceed. Patent infringement issues remained governed by the specific claims, products, and later litigation between the parties.

What does the case mean for biosimilar launch strategy?

The decision changed the risk calculation for biosimilar applicants.

An applicant may decline to provide the application and manufacturing information, but that choice can allow the reference sponsor to pursue patent litigation through other statutory routes. The applicant also loses the structured information exchange that can narrow the dispute.

A biosimilar company must therefore evaluate:

• Whether to participate in the patent dance.
• Whether to provide commercial-marketing notice before or after approval.
• Whether to launch at risk.
• Whether to seek declaratory relief.
• Whether to design around formulation and process patents.
• Whether to settle before approval or launch.
• Whether state-law remedies create additional exposure.

For reference-product sponsors, the decision reduced procedural control over timing. Patent portfolios must rely more heavily on enforceable claims covering manufacturing, formulation, devices, and specific methods of use.

Key Takeaways

• Sandoz Inc. v. Amgen Inc., 3:13-cv-02904, was the leading BPCIA case involving Zarxio and Neupogen.
• The Supreme Court held that the BPCIA does not provide a federal injunction to enforce the application-disclosure requirement.
• Biosimilar applicants may provide commercial-marketing notice before FDA approval.
• Zarxio received FDA approval on March 6, 2015, and launched in September 2015.
• The case was not a Paragraph IV or Orange Book dispute.
• Expiration of Amgen's foundational filgrastim patent reduced the blocking power of the Neupogen estate.
• Manufacturing, formulation, device, and method-of-use patents remained relevant sources of launch risk.
• The decision made patent-dance participation a strategic choice rather than a federally enforceable prerequisite to biosimilar marketing.

FAQs

What drug was at issue in Sandoz v. Amgen?

The case involved Sandoz's filgrastim biosimilar Zarxio and Amgen's reference biologic Neupogen. Filgrastim is a recombinant granulocyte colony-stimulating factor used to reduce infection risk associated with neutropenia.

Was Zarxio the first U.S. biosimilar?

Yes. FDA approved Zarxio on March 6, 2015, making it the first biosimilar approved in the United States.

Did Amgen win an injunction against Zarxio?

No. Amgen did not obtain an injunction blocking Zarxio's launch based on Sandoz's failure to disclose its application or its preapproval commercial-marketing notice.

Is Neupogen's patent estate still relevant?

The foundational filgrastim patent expired before Zarxio's launch. Later patents covering processes, formulations, presentations, devices, or methods may still matter for particular products and jurisdictions.

Does the Supreme Court decision apply to every biosimilar?

The decision establishes general rules for the BPCIA's application-disclosure and commercial-marketing notice provisions. Product-specific patent claims, FDA exclusivity periods, state-law issues, and later statutory amendments can produce different litigation outcomes.

References

1. Food and Drug Administration. (2015, March 6). FDA approves first biosimilar product Zarxio. U.S. Department of Health and Human Services.

2. Sandoz Inc. v. Amgen Inc., 582 U.S. 1, 137 S. Ct. 1664 (2017).

3. Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015).

4. Public Health Service Act, 42 U.S.C. § 262.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

6. U.S. Patent No. 5,580,755. (1996). DNA encoding human granulocyte colony stimulating factor. U.S. Patent and Trademark Office.